Sentences with phrase «cancer drug research»

Repurposed anticancer drugs such as aspirin and antacids may represent the future of cancer drug research, according to leaders of the ReDO project.

But these repurposed anticancer drugs such as antifungals and painkillers may represent the future of cancer drug research, according to leaders of the ReDO project.

The company focuses on cancer drug research and has a platform for so - called «real - world» data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

Not exact matches

There are also forums dedicated to policy issues such as drug pricing and medical standards — last year, former Vice President Joe Biden announced a federal Genomic Data Commons to expedite cancer research during a keynote address.

Now, here's a happy story: A combination of better screening, investments in drug research, and better lifestyle choices (including declines in cigarette smoking) may have helped lead to a downtick in the rate of cancer drug deaths.

or, more radically, for posting their genetic data to an anonymized, shared research database that might be used to identify those at risk for certain diseases or to identify those who respond better to specific classes of drugs, from beta blockers to cancer medicines.

When Kathy Giusti founded the Multiple Myeloma Research Foundation, there were no drugs for the blood cancer.

That research will be crucial: An earlier effort by another company, Pathway Genomics, to create a «liquid biopsy» for cancer was greeted in September by a stern letter from the Food and Drug Administration (FDA) warning that the agency had «not found any published evidence that this test or any similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals.»

This genomic information would then be fed to Watson, using its supercomputing powers and Sloan Kettering's oncology precision medicine database to sift through the latest cancer research and drug trials.

PERTH - based Medi - tech Research Limited may be on the brink of a major advance in cancer therapy with its hyaluronic acid technology for the delivery of anti-cancer drugs.

He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)- Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research.

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

Looking at sixty - seven recent drug discovery projects based on preclinical cancer biology research, they found that in more than 75 percent of cases the published data did not match up with their in - house attempts to replicate.

DMBA is another cancer - generating drug used in research because it causes mutations in cells.

The facility is involved in drug development and conducts clinical research for cancer treatment.

Nanophotonics research by materials scientist Jennifer Dionne could lead to improved drugs, cancer tests or invisibility cloaks.

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.

The new research, published recently as two separate studies in ACS Central Science and the Journal of the American Chemical Society, demonstrates that a new class of drugs called small molecule RNA inhibitors can successfully target and kill specific types of cancer.

«Once this novel tumor - homing agent binds to the EphA2 receptor, the oncogene functions as a cancer - specific molecular Trojan horse for paclitaxel, carrying the drug inside the cancel cell, killing the cell, and thwarting metastasis,» said Maurizio Pellecchia, a professor of biomedical sciences at UCR's School of Medicine who led the research.

«Because this binding causes EphA2 internalization, we also sought to conjugate 123B9 with paclitaxel and thus direct the drug to migrating cancer cells,» said Pellecchia, who holds the Daniel Hays Chair in Cancer Research acancer cells,» said Pellecchia, who holds the Daniel Hays Chair in Cancer Research aCancer Research at UCR.

A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.

«Molecular Trojan horse delivers chemotherapeutic drug to cancer cells: Research offers valuable insights into halting metastasis.»

«The fine particles of this drug allow for it to be released slowly and stay in the abdomen,» said Katherine Roby, Ph.D., research associate professor in the Department of Anatomy and Cell Biology at KU Medical Cancer, who started her pre-clinical work on Nanotax more than a decade ago.

Student Research Helps Discover Cancer Drugs Cancer drug design provided a challenging PhD dissertation topic for Almut Mecke, a physics student at University of Michigan.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hcancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HCancer Center at UC San Diego Health.

Avastin, a drug to treat colorectal cancer, for example, grew out of a scientist's discretionary research that was only peripherally related to the main project.

McKenna and his team have identified four different drugs — including the anti-HIV drug nelfinavir — that can disrupt the process by which hypoxia occurs, restoring proper blood flow to the tumours and making them more vulnerable to chemotherapy (Cancer Research, DOI: 10.1158 / 0008 - 5472.

Appearing alongside the heads of five of NIH's 27 institutes and centers, Collins instead offered examples of how NIH research has led to new drugs for cystic fibrosis and cancer treatments that help the immune system fight tumors.

The research suggests that immune therapy for cancer might be more effective if combined with drugs that inhibit NF - kB.

An experimental drug in early development for aggressive brain tumors can cross the blood - brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James).

The long term use of proton pump inhibitors (PPIs), a class of drugs commonly used to treat acid reflux, is linked to a more than doubling in the risk of developing stomach cancer, finds research published online in the journal Gut.

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Rescancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer ResCancer Discovery, a journal of the American Association for Cancer ResCancer Research.

«This research is highly significant as it implies that a commercially available drug, amphotericin B, which has never been used before for patients with gliomas, may be a novel treatment to consider in future trials of patients with this frequently lethal cancer,» says Dr. Rutka.

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) has identified a mechanism by which cancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibcancer cells develop resistance to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.

A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cCancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cancercancer.

In science news around the world, NASA's Cassini mission is about to take its final plunge into the atmosphere of Saturn after 13 years providing an unprecedented view of the planet and its moons, a fight over whether to preserve or develop of one Europe's oldest gold mining sites heats up again, the U.S. Food and Drug Administration approves the first cancer gene therapy for people, a U.S. court gives a green light to a $ 1 billion lawsuit brought by the Guatemalan victims and survivors of mid — 20th century syphilis experiments by research institutions including Johns Hopkins University, and more.

To address this challenge, our research group is using nanoparticles not only to deliver more chemotherapy drugs to the target site within cancer cells, but also to compromise the function of the efflux pumps and thereby significantly improve safety and efficacy of cancer therapy.»

«Everyone is working on these [drugs] like crazy,» says David Lane, a cancer biologist at the Agency for Science, Technology and Research in Singapore, and a co-discoverer of p53.

More importantly, it opens up exciting avenues of research to explore how restoration of p53 with drugs such as those that target ERAP1 can help to harness the immune system to recognise and destroy cancer cells.»

Funding from the NIH / National Cancer Institute (grants CA158372, CA136017, CA136017, F31CA171733) and a New Drug State Key Project grant (009ZX09102 - 205) helped support this research.

The U.S. attorney's office in Indianapolis had alleged that Guoqing Cao and Shuyu Li, both naturalized U.S. citizens and senior biologists at Eli Lilly, passed research on tailored therapies for cancer and drugs to treat diabetes, obesity, and other metabolic disorders to Jiangsu Hengrui Medicine, a company in Lianyungang, China.

Research led by scientists at Dana - Farber Cancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatCancer Institute showed the drug and a potentiating agent lengthened the lives of patients with metastatic colorectal cancer, all of whom had exhausted available standard treatcancer, all of whom had exhausted available standard treatments.

New products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impact.

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

A simple colour changing test to help scientists investigate potential cancer drugs has been developed by University of Bath scientists, allowing research to progress at a much greater speed than has been possible until now.

On the other hand, the emergence of new products such as drugs for cancer, HIV / AIDS, and rare diseases, as well as progress in stem cell research, are strong positives in the industry's favor.

«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.